Hologic Inc. (HOLX) shares plummeted by 5.49% in pre-market trading on Thursday, following a series of analyst downgrades after the company reported its fiscal first-quarter results.
Leerink downgraded HOLX to Market Perform from Outperform with a lower price target of $75, down from $80, citing the mixed Q1 report. Jefferies also cut its price target on the stock to $78 from $85, while JP Morgan lowered its target to $85 from $94.
The downgrades came as analysts expressed concerns over the company's outlook and financial performance. Hologic's Q1 results fell short of market expectations, leading analysts to revise their ratings and price targets accordingly.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。